BioCryst Pharmaceuticals BCRX Non-cash interest expense on royalty financing obligations
Non-cash interest expense on royalty financing obligations at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations?
- BioCryst Pharmaceuticals (BCRX) reported non-cash interest expense on royalty financing obligations of $13.29M in Q1 2026.
- How has BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations changed year-over-year?
- BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations decreased by 1.6% year-over-year, from $13.51M to $13.29M.
- What does non-cash interest expense on royalty financing obligations mean?
- Represents the non-cash portion of interest expense recognized on financing arrangements backed by future royalty streams. This accounting entry reflects the accretion of the liability over the life of the financing agreement. It is essential for reconciling net income to operating cash flow, as it represents a financing cost that does not impact immediate cash liquidity.